Inhalers and how they work
Last reviewed November 17, 2026. OwieClear editorial team. Waiting for clinician review. Not medical advice. Talk with your doctor about your own care.
COPD inhalers come in three active ingredients, combined in various ways. Knowing which of the three is in your device tells you most of what it does.
The newest part of the decision is whether an inhaled steroid belongs in the mix, and that now depends partly on a blood test.
Related pages: COPD (chronic lung disease)
The bottom line
- Short-acting relievers are for immediate symptoms.
- Long-acting bronchodilators, LAMA and LABA, are the maintenance foundation.
- Inhaled steroids help some people with COPD and raise pneumonia risk in others.
- A blood eosinophil count helps predict who benefits from inhaled steroids.
- Triple therapy combines all three for people with continuing exacerbations.
- The best thresholds for using eosinophils to guide treatment.
- Who can safely step down from inhaled steroids.
- Whether any inhaled treatment slows functional decline.
The story, step by step
What the evidence labels mean
The rescue inhaler
What happens
Fast, short, as needed.
What the research shows
- Short-acting beta-agonists such as albuterol or salbutamol relax airway muscle within minutes and last a few hours.
- Short-acting antimuscarinics such as ipratropium work slightly more slowly and last a little longer.
- They are used as needed for breathlessness, and everyone with COPD should have one.
- They relieve symptoms but do nothing about the underlying disease, so they are not a substitute for maintenance treatment.
- Needing a reliever far more often than usual is one of the early signs of an exacerbation, and is worth tracking.
- Side effects include tremor and palpitations with beta-agonists, and dry mouth with antimuscarinics.
Why it matters
Reliever use is a useful early-warning signal. A change in how often it is needed usually precedes a flare-up by days.
What's still uncertain
- How best to track reliever use in practice.
- Whether smart inhalers that record use improve outcomes.
Read more
- NHLBI: COPD treatmentGovernment
- MedlinePlus: COPDGovernment
- GOLD: Global Initiative for Chronic Obstructive Lung DiseaseNonprofit
Next: The foundation
LAMA and LABA
What happens
Long-acting, taken every day.
What the research shows
- Long-acting antimuscarinics, LAMAs, such as tiotropium, umeclidinium and glycopyrronium, work for 12 to 24 hours.
- Long-acting beta-agonists, LABAs, such as formoterol, salmeterol and vilanterol, relax airway muscle by a different route.
- Both reduce breathlessness, improve exercise capacity and reduce exacerbations, and combining them works better than either alone.
- A key benefit is reducing hyperinflation, which is why people often report being able to walk further even when spirometry barely changes.
- LAMAs appear somewhat more effective than LABAs at preventing exacerbations.
- They are maintenance treatment and must be taken daily, including on days when breathing feels fine. This is the most common misunderstanding about them.
Why it matters
Maintenance inhalers taken only when symptomatic deliver almost none of their benefit, and this mistake is extremely common.
What's still uncertain
- The best combination for individual patients.
- Whether any of these slow the decline in lung function.
Read more
- NHLBI: COPD treatmentGovernment
- GOLD: Global Initiative for Chronic Obstructive Lung DiseaseNonprofit
- MedlinePlus: COPDGovernment
Next: Steroids
When they help, and when they do not
What happens
Not for everyone, unlike asthma.
What the research shows
- Inhaled corticosteroids reduce airway inflammation. In asthma they are central; in COPD their role is selective.
- They reduce exacerbations in people who have frequent ones, and in those with features of asthma overlap.
- They also increase the risk of pneumonia in COPD, along with oral thrush, hoarseness and bruising.
- The decision now uses the blood eosinophil count: higher counts predict benefit, and low counts predict little benefit with the same pneumonia risk.
- They are not used alone in COPD, always in combination with a long-acting bronchodilator.
- Rinse your mouth after using one, which substantially reduces thrush and hoarseness.
Why it matters
The pneumonia trade-off is the reason inhaled steroids are not given to everyone with COPD, and it is the clearest difference from asthma treatment.
What's still uncertain
- The best eosinophil thresholds for the decision.
- Who can safely withdraw inhaled steroids.
Read more
- GOLD: Global Initiative for Chronic Obstructive Lung DiseaseNonprofit
- NHLBI: COPD treatmentGovernment
- MedlinePlus: COPDGovernment
Next: Triple therapy
All three together
What happens
For continuing exacerbations.
What the research shows
- Triple therapy combines a LAMA, a LABA and an inhaled corticosteroid, usually in one device.
- It is used for people who continue to have exacerbations despite dual bronchodilator treatment, particularly with higher eosinophil counts.
- Trials have shown reduced exacerbations, and some have shown reduced mortality compared with dual therapy.
- A single device improves adherence compared with taking three separate inhalers.
- Stepping down from triple therapy is possible in selected people and should be planned rather than improvised, as exacerbations can return.
- Escalation should follow a review of whether the inhaler is being used correctly, because poor technique is a far more common reason for failure than an inadequate drug.
Why it matters
Before adding a third drug, the useful question is whether the first two are reaching the lungs at all. Often they are not.
What's still uncertain
- Who can step down safely.
- Whether the mortality benefit is robust.
Read more
- GOLD: Global Initiative for Chronic Obstructive Lung DiseaseNonprofit
- NHLBI: COPD treatmentGovernment
- American Lung AssociationNonprofit
Next: The other medicines
Beyond inhalers
What happens
A short list, used selectively.
What the research shows
- Oral corticosteroids are used in short courses for exacerbations, not long term, because prolonged use causes osteoporosis, diabetes, muscle weakness and infection risk.
- Azithromycin taken long term reduces exacerbations in selected patients, with trade-offs including hearing effects, heart rhythm and antibiotic resistance.
- Roflumilast reduces exacerbations in severe disease with chronic bronchitis, and commonly causes nausea, diarrhoea and weight loss.
- Mucolytics such as carbocisteine help some people with persistent sputum.
- Theophylline is now rarely used, because the margin between effective and toxic doses is narrow.
- Alpha-1 augmentation therapy is specific to alpha-1 antitrypsin deficiency.
- Vaccination against influenza, COVID-19, pneumococcus and RSV is part of treatment, because infections drive exacerbations.
Why it matters
Long-term oral steroids are still prescribed for COPD in some places. They are not recommended for maintenance, and the harms accumulate quietly.
What's still uncertain
- Who benefits most from long-term azithromycin.
- The role of mucolytics in modern practice.
Read more
- NHLBI: COPD treatmentGovernment
- GOLD: Global Initiative for Chronic Obstructive Lung DiseaseNonprofit
- CDC: Vaccines for adultsGovernment